KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Boston Scientific (BSX) Operating Expenses (2016 - 2026)

Boston Scientific's Operating Expenses history spans 18 years, with the latest figure at $2.5 billion for Q1 2026.

  • On a quarterly basis, Operating Expenses rose 9.83% to $2.5 billion in Q1 2026 year-over-year; TTM through Mar 2026 was $10.5 billion, a 13.74% increase, with the full-year FY2025 number at $10.2 billion, up 15.24% from a year prior.
  • Operating Expenses hit $2.5 billion in Q1 2026 for Boston Scientific, down from $2.9 billion in the prior quarter.
  • Over the last five years, Operating Expenses for BSX hit a ceiling of $2.9 billion in Q4 2025 and a floor of $1.6 billion in Q1 2022.
  • Historically, Operating Expenses has averaged $2.1 billion across 5 years, with a median of $2.0 billion in 2023.
  • Biggest five-year swings in Operating Expenses: decreased 7.34% in 2022 and later rose 24.87% in 2024.
  • Tracing BSX's Operating Expenses over 5 years: stood at $1.8 billion in 2022, then increased by 9.02% to $2.0 billion in 2023, then grew by 21.3% to $2.4 billion in 2024, then rose by 17.93% to $2.9 billion in 2025, then decreased by 11.95% to $2.5 billion in 2026.
  • Business Quant data shows Operating Expenses for BSX at $2.5 billion in Q1 2026, $2.9 billion in Q4 2025, and $2.5 billion in Q3 2025.